

Genetic Testing

Policy Number: MCS040.01
Approval Date: April 20, 2021

[Instructions for Use](#)

Table of Contents	Page
Coverage Guidelines	1
• Tumor Markers	1
• Cytogenetic Studies	1
• Molecular Diagnostic Genetic Tests Included in the Palmetto MolDX Program	2
• Other Molecular Diagnostic Genetic Tests	2
Supporting Information	3
Policy History/Revision Information	21
Instructions for Use	21

Related Medicare Advantage Policy Guidelines
• Blood Product Molecular Antigen Typing
• BRCA1 and BRCA2 Genetic Testing
• Cytogenetic Studies (190.3)
• Genetic Testing for Lynch Syndrome
• Molecular Pathology Procedures for Human Leukocyte Antigen (HLA) Typing
• Molecular Pathology/Genetic Testing Reported with Unlisted Codes
• Molecular Pathology/Molecular Diagnostics/Genetic Testing
• Tier 2 Molecular Pathology Procedures

Coverage Guidelines

Genetic testing and counseling are covered when Medicare coverage criteria are met.

Note: Screening services, such as predictive and pre-symptomatic genetic tests and services, are those used to detect an undiagnosed disease or disease predisposition, and as such are not a Medicare benefit and not covered by Medicare. However, Medicare does cover a broad range of legislatively mandated preventive services to prevent disease, detect disease early when it is most treatable and curable, and manage disease so that complications can be avoided. These services can be found on the CMS website at http://www.cms.hhs.gov/prevntiongeninfo/01_overview.asp. (Accessed April 9, 2021)

Tumor Markers

Tumor markers are covered when criteria are met; refer to the following NCDs:

- [Tumor Antigen by Immunoassay – CA 125 \(190.28\)](#) (Accessed April 5, 2021)
- [Tumor Antigen by Immunoassay – CA 19-9 \(190.30\)](#) (Accessed April 5, 2021)
- [Tumor Antigen by Immunoassay – CA 15-3/CA 27.29 \(190.29\)](#) (Accessed April 5, 2021)
- [Carcinoembryonic Antigen \(190.26\)](#) (Accessed April 5, 2021)
- [Prostate Specific Antigen \(190.31\)](#) (Accessed April 5, 2021)
- [Alpha-fetoprotein \(190.25\)](#) (Accessed April 5, 2021)

Cytogenetic Studies

Cytogenetic studies are used to describe the microscopic examination of the physical appearance of human chromosomes. Cytogenetic studies are covered when reasonable and necessary for the diagnosis or treatment of the following conditions:

- Genetic disorders (e.g., mongolism) in a fetus;
- Failure of sexual development;
- Chronic myelogenous leukemia;
- Acute leukemias lymphoid (FAB L1-L3), myeloid (FAB M0-M7), and unclassified; or
- Myodysplasia

Refer to the [National Coverage Determination \(NCD\) for Cytogenetic Studies \(190.3\)](#). (Accessed April 9, 2021)

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Refer to the [Molecular Diagnostic Genetic Tests included in the Palmetto MoIDX Program](#) table for specific LCDs/LCAs and applicable coverage guidelines.

Note: The [Molecular Diagnostic Genetic Tests included in the Palmetto MoIDX Program](#) table is a list, but not all-inclusive, of tests that have completed the MoIDX Technical Assessment Process. For the most current MoIDX information go to [MoIDX Coding and Billing Guidelines](#).

Other Molecular Diagnostic Genetic Tests

MyPRS™ Test for Multiple Myeloma Gene Expression Profile (CPT code 81479)

Medicare does not have a National Coverage Determination (NCD) for MyPRS™ test for multiple myeloma gene expression profile. Local Coverage Determinations (LCDs)/Local Coverage Article (LCAs) exist and compliance with these policies is required where applicable. For specific LCDs/LCAs, refer to the table for [MyPRS™ Test for Multiple Myeloma Gene Expression Profile](#).

For coverage guidelines for states/territories with no LCDs/LCAs, refer to the UnitedHealthcare Commercial Medical Policy titled [Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions](#).

Note: After checking the [MyPRS™ Test for Multiple Myeloma Gene Expression Profile](#) and searching the [Medicare Coverage Database](#), if no LCD/LCA is found, then use the policy referenced above for coverage guidelines.

PancaGEN® (Powered by Pathfinder TG) (CPT code 81479)

Medicare does not have a National Coverage Determination (NCD) for PancaGEN®. Only one contractor has Local Coverage Determinations (LCDs) which address, i.e., Novitas Solutions, Inc., for the following states: AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, and TX. Compliance with these LCDs is required where applicable. Refer to the LCD for Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG® (L34864). This test is provided to Medicare beneficiaries throughout the United States by Interpace Diagnostics in Pittsburgh, PA.

For coverage and payment information for all states/territories, refer to the [LCD for Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG® \(L34864\)](#).

Notes:

- After searching the [Medicare Coverage Database](#), if no LCD/LCA is found, then use the policy referenced above for coverage guidelines.
- For additional Medicare guidance, refer to the [Medicare Managed Care Manual Chapter 4, §90.4.1 – MAC with Exclusive Jurisdiction over a Medicare Item or Service](#). (Accessed April 5, 2021)

Next Generation Sequencing (NGS)

For coverage guidelines, refer to the [NCD for Next Generation Sequencing \(NGS\) \(90.2\)](#) (Accessed April 5, 2021). Local Coverage Articles (LCAs) exist and compliance with these LCAs is required where applicable. For specific LCDs/LCAs, refer to the table for [Next Generation Sequencing \(NGS\)](#).

NGS Test Description

Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, in vitro companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variations as a laboratory diagnostic test, such as when used as a companion in vitro diagnostic test.

NGS is not a specific test but a sequencing methodology utilized to capture genomic information. Unlike Sanger sequencing (the prior standard technology) that typically provides sequence information for a single DNA strand/molecule, NGS allows for massively parallel sequencing of millions of DNA molecules concurrently [9, 10]. This allows for capturing many relevant genomic targets simultaneously, usually by utilizing capture technologies such as by PCR amplification or hybrid capture. As

such, NGS tests for use in cancer are often comprised of gene panels whose content is either relevant to a specific tumor type or condition, or a larger panel of genes that can be used for multiple tumor types, including in hematopoietic malignancies.

NGS tests can vary significantly for many reasons. While NGS defines a broad methodology for massively parallel sequencing, different technologies that have different strengths, weaknesses, and technical limitations or liabilities are available [11]. The most common sequencing platforms in clinical use today are from Illumina and Thermo Fisher. While both sequence by synthesis similar to Sanger sequencing, these platforms utilize different chemistries, signal amplification, and detection methods. Gene panels can include only the portions of genes that contain the most critical clinically-relevant information, or be comprehensive, containing entire exonic gene regions (coding regions), introns (non-coding regions), and even sequence RNA for detecting gene fusions. Downstream from the pre-analytic processes mentioned above, the bioinformatics used to process and assess the resultant sequencing reads and identify variants/mutations can yield different results based on the software used and what variant types of variants the test is attempting to detect. These software tools must take the resultant sequencing file (generally starting with the FASTQ format), align all possible sequences with a reference genome (BAM/SAM), and identify variants from the reference (typically a VCF file) [6]. Once such variants are identified, they must be assessed for validity and subsequently for their clinical relevance. The types of genomic information reported can vary, as tests can uncover a myriad of genomic alterations such as single nucleotide variants (SNVs), Insertions/Deletions (INDELs), Copy Number Alterations (CNAs; these can be simply amplifications at a single locus or chromosomal gains and losses), and gene fusions/translocations. The resultant information can also be used to calculate additional relevant information, such as Tumor Mutation Burden (TMB), or the presence of microsatellite instability (MSI). All of these variant classes have demonstrated clinical utility. As such, NGS testing in cancer comprises a large heterogeneous group of assays that are substantially different from each other. Additionally, NGS testing is highly complex and requires expertise from handling the specimen, to running complex equipment, to understanding the required bioinformatics, to interpreting the findings and creating an actionable medical report.

Two types of tests are considered for coverage, “Hot-spot” tests and comprehensive genomic profile tests (CGP). The definition of these terms, in addition to appropriate coding information is located in Billing and Coding Articles associated with this LCD. These tests can detect any combination of the previously described variant types, but in general, Hot-spot tests are limited to SNVs and small INDELs, whereas CGPs can detect those variants in addition to CNAs, larger INDELs, gene fusions/translocations, and be used to calculate MSI status and TMB when relevant.

Refer to the [MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies \(L38176\)](#). (Accessed April 22, 2021)

Pharmacogenomic Testing for Warfarin Response (CYP2C9 and VKORC1) (CPT codes 81227 and 81355)

Effective August 3, 2009, the Centers for Medicare & Medicaid Services (CMS) believes that the available evidence supports that coverage with evidence development (CED) under §1862(a)(1)(E) of the Social Security Act (the Act) is appropriate for pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness by any method, and is therefore covered only when provided to Medicare beneficiaries who are candidates for anticoagulation therapy with warfarin who meet the criteria outlined in the [NCD for Pharmacogenomic Testing for Warfarin \(90.1\)](#). (Accessed April 5, 2021)

The list of Medicare approved clinical trials is available at <http://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Pharmacogenomic-Testing-for-Warfarin-Response.html>. (Accessed April 5, 2021)

For payment rules for NCDs requiring CED, refer to the Coverage Summary titled [Experimental Procedures and Items, Investigational Devices and Clinical Trials](#).

Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these LCDs/LCAs is required where applicable. These policies are available at <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>.

Supporting Information

Important Note: When searching the [Medicare Coverage Database](#), if no LCD/LCA is found, then use the applicable referenced default policy below for coverage guidelines.

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
4Kscore® Assay	81539	L36763 (A56932)	L37120 (A57336) L37122 (A57337)	L36979 (A56944)	L37013 (A57556)	L37792 (A56653)		L37798 (A56287)
4q25-AF Risk Genotype Coding	81479	A53457	A55091 A55090	L36021 (A54241)	L36807 (A55137)			
9p21 Genotype Test	81479	A53657	A55093 A55092	L36021 (A54242)	L36807 (A55138)			
Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	81120 81121	L35025 (A55695)	L35160 (A55711) L36256 (A55712)	L36021 (A55716)	L36807 (A55738)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
Afirma™ Assay by Veracyte	81546	L35025 (A53098)	L35160 (A54356) L36256 (A54358)	L36021 (A54185)	L36807 (A55138)	L35396 (A52986)	L35000 (A56199)	
APC and MUTYH Gene Testing	81201 81202 81203 81401 81403 81406 81435 81436 81479 0157U	L36827 (A56824)	L36882 (A57352) L36884 (A57353)	L36910 (A56828)	L37224 (A56901)	L35062 (A56541)	L35000 (A56199)	
AlloMap	81595	L35025 (A53099)	L35160 (A54364) L36256 (A54366)	L36021 (A54186)	L36807 (A55140)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
AlloSure® or Equivalent Cell-Free DNA Testing for Kidney and Heart Allografts	81479	L38255 (A58387)	L38355 (A57380) L38380 (A57233)	L38272 (A57167)	L38439 (A57096)			
Androgen Receptor Variant (AR-V7) Protein Test	81479	L37701 (A56964)	L37744 (A57499) L37746 (A57601)	L37836 (A57158) Effective 05/09/21	L37915 (A57102)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					
			Noridian	CGS	WPS	Novitas	NGS	First Coast
ApoE Genotype	81401	A53652	L36358 (A55094) L36362 (A55095)	L36021 (A54244)	L36807 (A55141)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy (ARVD/C) Testing	81439	L36129 (A53605)	L36358 (A54975) L36362 (A54976)	L36021 (A54685)	L36807 (A55235)			
Aspartoacylase 2 Deficiency (ASPA) Testing	81200 81412 81443 81479	A53602	A55089 A55088	L36021 (A54253)	L36807 (A55142)			
ATP7B Gene Tests	81406 81443 81479	A53550	A55097 A55098	L36021 (A54254)	L36807 (A55143)			
Avise PG	84999	L35025 (A53100)	L35160 (A54376) L36256 (A54378)	L36021 (A54187)	L36807 (A55144)			
BCKDHB Gene Test	81205 81206 81443	A53600	A55100 A55099	L36021 (A54255)	L36807 (A55145)			
BCR-ABL Negative Myeloproliferative Disease	81206 81207 81208 81219 81270 81279 81338 81339 81450 81479 0027U 0040U	L36044 (A56959)	L36180 (A57421) L36186 (A57422)	L36117 (A56999)	L36815 (A57570)			
BDX-XL2	0080U	L37031 (A56929)	L37054 (A57356) L37062 (A57357)	L37134 (A56947)	L37216 (A57558)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Biomarkers in Cardiovascular Risk Assessment	82172	L36129	L36358	L36139	L36523			
	82610	(A56943)	(A57037)	(A57386)	(A57559)			
	83090		L36362					
	83695		(A57055)					
	83698							
	83700							
	83701							
	83704							
	83719							
	83721							
86141								
bioTheranostics CancerTYPE ID®	81540	L35025	L35160	L36021	L36807	L35396	L35000	
		(A53101)	(A54386)	(A54188)	(A55147)	(A52986)	(A56199)	
Lab: Bladder/Urothelial Tumor Markers	88120	L33420	L36678	A56471	L36807			
	88121	(A53095)	(A55028)		(A56332)			
	86294		L36680					
	86316		(A55029)					
	86386							
BLM Gene Analysis	81209	A53540	A55114	L36021	L36807			
	81443		A55113	(A54256)	(A55148)			
Blood Product Molecular Antigen Typing	81105	A58308	A57376	A57155	A57110			
	81106		A57124					
	81107							
	81108							
	81109							
	81110							
	81111							
	81112							
	81403							
	0001U							
	0084U							
	0180U							
	0181U							
	0182U							
	0183U							
	0184U							
0185U								
0186U								

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
	0187U 0188U 0189U 0190U 0191U 0192U 0193U 0194U 0195U 0196U 0197U 0198U 0199U 0200U 0201U 0221U 0222U							
BluePrint®	81479	A53484	A55116 A55115	L36021 (A54257)	L36807 (A55146)			
Breast Cancer Assay: Prosigna	81520	L36125 (A56949)	L36380 (A57363) L36386 (A57364)	L36425 (A56989)	L36811 (A57560)			
Breast Cancer Index® (BCI) Gene Expression Test	81518	L37794 (A56875)	L37822 (A57773) L37824 (A57774)	A56884	L37913 (A56335)			
BRCA1 and BRCA2 Genetic Testing	81163 81164 81165 81166 81167 81212 81215 81216 81217 81432 81433 81479 0102U	L36082 (A56854)	L36161 (A57354) L36163 (A57355)	L36456 (A56971)	L36813 (A57771)	L36715 (A56542)		L36499 (A57449)

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
	0103U 0129U 0131U 0132U 0133U 0134U 0135U 0136U 0137U 0138U 0157U 0158U 0159U 0160U 0161U 0162U 81162 81445 81455							
CDH1 Genetic Testing	81406	A54835	A55971 A55970	A54878	L36807 (A55622)			
CHD7 Gene Analysis	81407 81479	A53565	A55085 A55086	L36021 (A54243)	L36807 (A55157)			
Circulating Tumor Cell Marker Assays	86152 86153	L35071 (A56873)	L34066 (A57815) L35710 (A57816)	L36973 (A57288)				
ClonoSEQ® Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies	81479	A56270	A56322 A56323	A56307	A56277			
ConfirmMDx Epigenetic Molecular Assay	81551	L35632 (A56955)	L36327 (A57605) L36329 (A57606)	L36006 (A57031)	L37005 (A55540)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Controlled Substance Monitoring and Drugs of Abuse Testing	80305	L35724	L36707	L36029		L35006		L36393
	80306	(A54799)	(A55030)	(A56818)		(A56645)		(A57077)
	80307		L36668					
	G0480		(A55001)					
	G0481							
	G0482							
	G0483							
	G0659							
	0143U							
	0144U							
	0145U							
	0146U							
	0147U							
	0148U							
	0149U							
	0150U							
0227U								
Corus® CAD Assay	81493	L37612 (A56930)	L37673 (A57415) L37675 (A57416)	A56950	L37770 (A57562)			
Cystatin C Measurement	82610	L37581 (A56948)	L37616 (A57643) L37618 (A57644)	A56988	L37768 (A57563)			L37561 (A57682)
Melanoma Risk Stratification Molecular Testing	81599 81529	L37725 (A56961)	L37748 (A57417) L37750 (A57418)	L38016 (A56990)	L38018 (A56636)			
DecisionDx-UM (Uveal Melanoma)	81552	L37033 (A56906)	L37070 (A57621) L37072 (A57622)	L37130 (A56981)	L37210 (A57566)			
EndoPredict Breast Cancer Gene Expression Test	81522	L37264 (A56963)	L37295 (A57607) L37311 (A57608)	L37356 (A56997)	L37663 (A57567)			
ENG and ACVRL1 Gene Tests	81405 81406 81479	A53536	A55181 A55182	A54262	L36807 (A55159)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test	81554	L37857 (A56898)	L37887 (A57419) L37891 (A57420)	L37905 (A56985)	L37919 A57568			
FANCC Genetic Testing	81242 81412 81443	A53628	A55183 A55184	A54263	L36807 (A55160)			
FDA Approved CLL Companion Diagnostic Test	88374 88377 88271 88275 88291	A56008	A56009 A56013	A56050	A56020			
FDA-Approved BRAF Tests	81210	L35025 (A54018)	L35160 (A54418) L36256 (A54420)	L35349 (A56882) L36021 (A54191)	L36807 (A55161) L36793 (A55135)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451) L34912 (A57439)
FDA-Approved EGFR Tests	81235	L35025 (A54021)	L36256 (A54424) L35160 (A54422)	L36021 (A54192)	L36807 (A55193)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
FDA-Approved KRAS Tests	81275	L35025 (A54472)	L35160 (A54498) L36256 (A54500)	L36021 (A56973)	L36807 (A55162)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification (NAATs)	87505 87506 0097U 87507	L37709 (A56593)	L37350 (A56706) L37368 (A56711)	L37364 (A56596)	L37766 (A56637)			
Fragile X	81243 81244 81470 81471	A53638	A55242 A55241	L36021 (A54264)	L36807 (A55163)			
GBA Genetic Testing	81251	A53542	A55243 A55244	L36021 (A54265)	L36807 (A55164)			
GlycoMark® Testing for Glycemic Control	84378 84999	L36761 (A56872)	L36864 (A57237) L36866 (A57238)	L36906 (A56565)				
HAX1 Gene Sequencing	81479	A53619	A55249 A55252	L36021 (A54266)	L36807 (A55165)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
HBB Full Gene Sequencing	81361 81362 81363 81364 81443	A53493	A55253 A55254	L36021 (A54267)	L36807 (A55166)			
HERmark Assay by Monogram	81479	L35025 (A53103)	L35160 (A54437) L36256 (A54439)	L36021 (A54193)	L36807 (A55167)			
HEXA Gene Analysis	81255 81406 81412 81443	A53598	A55255 A55256	L36021 (A54268)	L36807 (A55168)			
HLA-DQB1*06:02 Testing for Narcolepsy	81383	L36464 (A56857)	L36544 (A57441) L36551 (A57465)	L36485 (A56881)	L37003 (A57575)			
HLA Testing for Transplant Histocompatibility	81370 81371 81372 81375 81376 81378 81379 81380 81382	A56859	A57970 A57972	A56885	A57851			
HTTLPR Gene Testing	81479	A53480	A55264 A55265	L36021 (A54269)	L36807 (A55169)			
Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	81240 81241 81291	L36089 (A56899)	L36155 (A57423) L36159 (A57424)	L35984 (A56980)	L36400 (A57571)			
IKBKAP Genetic Testing	81260 81412 81443	A53596	A55612 A55613	L36021 (A54270)	L36807 (A55170)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Immunohistochemistry (IHC) Indications for Breast Pathology	88342	L35922	L36353	L36021	L36805			L36234 (A57708)
	88341	(A56838)	(A57614)	(A54271)	(A55136)			
	88360	(A53704)	(A55803)	(A56106)	(A55739)			
	88361	(A55718)	(A54597)	(A56536)	(A57733)			
Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer	81479	L37870 (A56924)	L37897	L37903	L37921			
			(A57664)	(A56982)	(A56333)			
KIF6 Genotype	81479	A53576	L37899					
			(A57665)					
Know error*	84999	A53554	L36021	L36807				
			(A54273)	(A55172)				
L1CAM Gene Sequencing	81407	A53659	A55273	L36021	L36807			
	81470		(A55272)	(A54272)	(A55171)			
LPA-Aspirin Genotype	81471		A55275					
	81479	A53467	A55277	L36021	L36807			
LPA-Intron 25 Genotype	81470		A55278	(A54274)	(A55192)			
	81471							
Lynch Syndrome Testing	81479	A53468	A55280	L36021	L36807			
	81210	A55279	(A54275)	(A55173)				
	81288	A53467	A55282	L36021	L36807			
	81292	A53468	(A55281)	(A54276)	(A55174)			
	81293	L35024	L36370	L35349	L36807	L35396	L35000	L34912
	81294	(A54987)	(A54995)	(A56882)	L36793	(A52986)	(A56199)	(A57450)
	81295	(A56072)	(A56103)	(A56106)	(A55135)			
	81296		L36374		(A55161)			
	81297		(A54996)					
	81298		(A56104)					
	81299							
	81300							
	81301							
	81317							
	81318							
	81319							
81403								
81432								

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
	81433 81435 81436 81445 81455 81479 88341 88342 0101U 0130U 0134U 0157U 0158U 0159U 0160U 0161U 0162U							
MammaPrint	81521	L35025 (A53104)	L36256 (A54447) L35160 (A54445)	L36021 (A54194)	L36807 (A55175)			
MCOLN1 Genetic Testing	81290 81412 81443	A53630	A55283 A55284	L36021 (A54277)	L36807 (A55176)			
MDS FISH	88271 88273 88274 88275 88291	L37602 (A56913)	L37620 (A57661) L37622 (A57662)	L37608 (A56926)	L37772 (A57576)			
MECP2 Genetic Testing	81302 81303 81304 81470 81471 81479	A53574	A55285 A55286	L36021 (A54278)	L36807 (A55189)			
Melanoma Risk Stratification Molecular Testing	81529 81599	L37725 (A56961)	L37748 (A57268) L37750 (A57290)	L38016 (A57165)	L38018 (A56636)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
MGMT Promoter Methylation Analysis	81287	L35974 (A56941)	L36188 (A57432) L36192 (A57433)	L36113 (A56983)	L37001 (A57577)			
Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors	81210	L35024 (A56072)	L36370 (A56103) L36374 (A56104)	A56106	L36793 (A56501)			L34912 (A57450) L36234 (A57708)
	81288							
	81292							
	81293							
	81294							
	81295							
	81296							
	81297							
	81298							
	81299							
	81300							
	81301							
	81317							
	81318							
	81319							
	81403							
	81432							
	81433							
	81435							
	81436							
81445								
81455								
81479								
88341								
88342								
0101U								
0130U								
0134U								
0157U								
0158U								
0159U								
0160U								
0161U								
0162U								
Minimal Residual Disease Testing for Colorectal Cancer	81479	L38290 (A58283)	A58448 A58449	L38305 (A58330)	L38431 (A57104)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Mitochondrial Nuclear Gene Tests	81479	A53669	A55290 A55291	L36021 (A54288)	L36807 (A55190)			
MMACHC Test	81404	A54035	A55288 A55289	L36021 (A54209)	L36807 (A55191)			
Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels	87631 87632 87633 87636 87637 0115U 0151U 0202U 0223U 0225U 0240U 0241U	L37713 (A56851)	L37301 (A57338) L37315 (A57340)	L37348 (A56974)	L37764 (A57579)			
MYPAP™	84999	A53544	A55292 A55293	L36021 (A54290)	L36807 (A55195)			
myPath Melanoma Assay	81479 0090U	L37859 (A56858)	L37881 (A57627) L37879 (A57626)	L37907 (A56878)	L37923 (A57580)			
Myriad's BRACAnalysis CDx™	81162	L35025 (A56854) L36082 (A54338)	L36256 (A55294) L35160 (A55295)	L36456 (A54689)	L36813 (A55224)			
NRAS Genetic Testing	81311 81479	L35073 (A56962)	L36335 (A57486) L36339 (A57487)	L35442 (A56998)	L36797 (A57581)			
NSD1 Gene Tests	81405 81406 81479	A53585	A55609 A55615	L36021 (A54291)	L36807 (A55198)			
OncoCee™	86152 86153	L35071 (A53112)	L34066 (A55593) L35710 (A55598)	L36021 (A54292)	A55245			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	0045U	L36912 (A56870)	L36941 (A57619) L36947 (A57620)	L36951 (A56887)	L37199 (A57583)			
Oncotype DX Breast Cancer Assay	81519	L35025 (A53105)	L36256 (A54482) L35160 (A54480)	L36021 (A54195)	L36807 (A55230)			
Oncotype DX Colon Cancer Assay	81525	L35025 (A53106)	L36256 (A54486) L35160 (A54484)	L36021 (A54196)	L36807 (A55231)	L35396 (A52986)	L35000 (A56199)	
PAX6 Gene Sequencing	81479	A53664	A55625 A55632	L36021 (A54293)	L36807 (A55199)			
Percepta® Bronchial Genomic Classifier	81479	L36854 (A56849)	L36886 (A57502) L36891 (A57504)	L36908 (A56972)	L37195 (A57584)			
Pharmacogenomics Testing	81220 81225 81226 81227 81231 81232 81247 81283 81306 81328 81335 81350 81355 81374 81377 81381 81383 81406 81479 0030U 0070U 0071U 0072U	L38294 (A58318)	L38335 (A57384) L38337 (A57385)	L38394 (A58324)	L38435 (A58395)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
	0073U 0074U 0075U 0076U							
Pigmented Lesion Assay	0089U	L38153 (A57868)	L38151 (A58052) L38153 (A58053)	L38111 (A57915)	L38178 (A57983)			
PIK3CA Gene Tests	81309 0155U	A53558	A55597 A55602	L36021 (A54295)	L36807 (A55200)			
Plasma-Based Genomic Profiling in Solid Tumors	81479 81445	L38043 (A57867)	L38119 (A57901) L38121 (A57905)	L38065 (A57917)	L38168 (A57936)		L37810 (A56867)	
PreDx®	81506	A53489	A55594 A55599	L36021 (A54296)	L36807 (A55201)			
Progenesa® PCA3 Assay	81313 0113U	L35025 (A53107) (A56853)	L36256 (A54492) (A57527) L35160 (A54489) (A57526)	L36021 (A54197) (A56973)	L36807 (A55202) (A57772)	L35396 (A52986)	L35000 (A56199)	L34519 (A57451)
Prolaris™ Prostate Cancer Genomic Assay	81541	L35869 (A56918) L37043 (A56911)	L36348 (A57509) L36350 (A57511)	L36002 (A57303)	L36787 (A57585)			
ProMark Risk Score	81479	L36665 (A56957)	L36704 (A57515) L36706 (A57609)	L36675 (A57034)	L37011 (A57587)			
Prometheus IBD sgi Diagnostic Policy	81479 82397 83520 86140	L37260 (A56933)	L37299 (A57516) L37313 (A57517)	L37352 (A56940)	L37539 (A57588)			
Prospera™	81479	L38041 (A57825)	A58045 A58046	L38059 (A57859)	L38174 (A57981)			
Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	81541 81542	L38292 (A58343)	L35160 (A57526) L36256 (A57527)	L38303 (A58371)	L38433 (A57106)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guidelines.

Test	Code	Palmetto MoIDX Program Guideline	LCDs/LCAs					First Coast
			Noridian	CGS	WPS	Novitas	NGS	
PTCH1 Gene Testing	81479	A53567	A55608 A55618	L36021 (A54297)	L36807 (A55203)			
ResponseDx Tissue of Origin®	81504	L35025 (A53108)	L36256 (A54496) L35160 (A54494)	L36021 (A54198)	L36807 (A55204)		L35000 (A56199)	
RPS19 Gene Tests	81405 81479	A53587	A55610 A55614	L36021 (A54299)	L36807 (A55205)			
SEPT9 Gene Test	81327	A53702	A55623 A55628	L36021 (A54300)	L36807 (A55206)			
SMPD1 Genetic Testing	81330 81412	A53624	A55627 A55631	L36021 (A54285)	L36807 (A55208)			
STAT3 Gene Testing	81405	A53562	A55480 A55481	L36021 (A54284)	L36807 (A55209)			
SULT4A1 Genetic Testing	81479	A53538	A55596 A55601	L36021 (A54283)	L36807 (A55210)			
TERC Gene Tests	81479	A53589	A55611 A55616	L36021 (A54282)	L36807 (A55211)			
ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer	0022U	L35025 (A55822)	L36256 (A55881) L35160 (A55888)	L36021 (A55851)	L36807 (A55846)	L35396 (A52986)		
TP53 Gene Test	81404 81405	A53591	A55487 A55484	L36021 (A54281)	L36807 (A55221)			
TruGraf Blood Gene Expression Test	81479	L38039 (A57350)	L38135 (A57746) L38137 (A57747)	L38053 (A57446)	L38160 (A57625)			
UGT1A1 Gene Analysis	81350	L35025 (A56853)	L36256 (A57527) L35160 (A57526)	L36021 (A56973)	L36807 (A57772)			
Vectra™ DA	81490	L35025 (A53110)	L36256 (A54505) L35160 (A54503)	L36021 (A54201)	L36807 (A55223)	L35062 (A56541)		
VEGFR2 Tests	81479	A53548	A55468 A55469	L36021 (A54279)	L36807 (A55232)			

Molecular Diagnostic Genetic Tests Included in the Palmetto MoIDX Program

Accessed April 9, 2021

* Also refer to the [MACs with corresponding States/Territories](#).

Note: Only use the WPS LCD/LCA if no other Part A LCD/LCA.

For states/territories with no LCDs/LCAs, refer to the applicable Palmetto MoIDX Program Guideline for coverage guideline.

Part A and B MACs	States/Territories
CGS Administrators, LLC	KY, OH
First Coast Service Options, Inc.	FL, PR, VI
National Government Services, Inc.	CT, IL, ME, MA, MN, NH, NY, RI, VT, WI
Noridian Healthcare Solutions, LLC	AK, AS, AZ, CA, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY
Novitas Solutions, Inc	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
Palmetto, GBA	AL, GA, NC, SC, TN, VA, WV
Wisconsin Physicians Service Insurance Corporation	AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

[Back to Guidelines](#)

MyPRS™ Test for Multiple Myeloma Gene Expression Profile

Accessed April 5, 2021

LCD/LCA ID	LCD/LCA Title	Contractor Type	Contractor Name	Applicable States/Territories
L35396 (A52986)	Biomarkers for Oncology	Part A and B MAC	Novitas Solutions, Inc.	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX

[Back to Guidelines](#)

Next Generation Sequencing (NGS)

Accessed April 9, 2021

LCD/LCA ID	LCD/LCA Title	Contractor Type	Contractor Name	Applicable States/Territories
A54901	Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Part A and B MAC	CGS Administrators, LLC	KY, OH
A57873	Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Part A and B MAC	CGS Administrators, LLC	KY, OH
A55624	Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Part A and B MAC	Noridian Healthcare Solutions, LLC	AS, CA, GU, HI, MP, NV
A56518	Billing and Coding: MoIDX: Targeted and	Part A and B MAC	Noridian Healthcare Solutions, LLC	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

Next Generation Sequencing (NGS)

Accessed April 9, 2021

LCD/LCA ID	LCD/LCA Title	Contractor Type	Contractor Name	Applicable States/Territories
	Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer			
A54795	Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Part A and B MAC	Palmetto GBA	AL, GA, NC, SC, TN, VA, WV
A57837	Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Part A and B MAC	Palmetto GBA	AL, GA, NC, SC, TN, VA, WV
A55197	Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Part A MAC	Wisconsin Physicians Service Insurance Corporation	AK*, AL*, AR, AZ*, CA*, CO, CT, DE, FL, GA*, HI*, IA, ID*, IL, IN, KS, KY*, LA, MA, MD, ME, MI, MO, MS, MT*, NC*, ND*, NE, NH, NJ, NM, NV*, OH*, OK, OR*, PA, RI, SC*, SD*, TN*, TX, UT*, VA*, VT, WA*, WI, WV*, WY* Note: States notated with an asterisk should follow the other available state-specific LCD/LCD listed on this grid. This WPS LCD/LCA only applies to states without asterisk.)
A55197	Part Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Part B MAC	Wisconsin Physicians Service Insurance Corporation	IA, IN, KS, MI, MO, NE
A57878	Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Part A MAC	Wisconsin Physicians Service Insurance Corporation	AK*, AL*, AR, AZ*, CA*, CO, CT, DE, FL, GA*, HI*, IA, ID*, IL, IN, KS, KY*, LA, MA, MD, ME, MI, MO, MS, MT*, NC*, ND*, NE, NH, NJ, NM, NV*, OH*, OK, OR*, PA, RI, SC*, SD*, TN*, TX, UT*, VA*, VT, WA*, WI, WV*, WY* Note: States notated with an asterisk should follow the other available state-specific LCD/LCD listed on this grid.

Next Generation Sequencing (NGS)				
Accessed April 9, 2021				
LCD/LCA ID	LCD/LCA Title	Contractor Type	Contractor Name	Applicable States/Territories
				This WPS LCD/LCA only applies to states without asterisk.
A57878	Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Part B MAC	Wisconsin Physicians Service Insurance Corporation	IA, IN, KS, MI, MO, NE
Back to Guidelines				

Policy History/Revision Information

Date	Summary of Changes
04/20/2021	<p>Template Update</p> <ul style="list-style-type: none"> Reformatted policy; transferred content to new template <p>Coverage Guidelines</p> <p><i>Next Generation Sequencing (NGS)</i></p> <ul style="list-style-type: none"> Replaced language with the <i>NGS Test Description</i> provided in the referenced National Coverage Determination (NCD) titled <i>Next Generation Sequencing (NGS) (90.2)</i> Added reference link to the LCD titled <i>MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38176)</i> <p>Supporting Information</p> <ul style="list-style-type: none"> Updated list of available Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) to reflect the most current reference links

Instructions for Use

This information is being distributed to you for personal reference. The information belongs to UnitedHealthcare and unauthorized copying, use, and distribution are prohibited. This information is intended to serve only as a general reference resource and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Each benefit plan contains its own specific provisions for coverage, limitations, and exclusions as stated in the Member's Evidence of Coverage (EOC)/Summary of Benefits (SB). If there is a discrepancy between this policy and the member's EOC/SB, the member's EOC/SB provision will govern. The information contained in this document is believed to be current as of the date noted.

The benefit information in this Coverage Summary is based on existing national coverage policy; however, Local Coverage Determinations (LCDs) may exist and compliance with these policies are required where applicable.

There are instances where this document may direct readers to a UnitedHealthcare Commercial Medical Policy, Medical Benefit Drug Policy, and/or Coverage Determination Guideline (CDG). In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

CPT® is a registered trademark of the American Medical Association.